Arunim Shah

Dr. Arunim Shah

Stem Cell Research Center, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
SKShobhita Katiyar
Shobhita Katiyar
ASArunim Shah
Arunim Shah
KRKhaliqur Rahman
Khaliqur Rahman
NTNaresh Kumar Tripathy
Naresh Kumar Tripathy
RKRajesh Kashyap
Rajesh Kashyap
CCChandra Prakash Chaturvedi
Chandra Prakash Chaturvedi
Erythropoiesis is a highly regulated process and undergoes several genotypic and phenotypic changes during differentiation. The phenotypic changes can be evaluated using a combination of cell surface markers expressed at different cellular stages of erythropoiesis using FACS. However, limited studies are available on the in-depth phenotypic characterization of progenitors from human adult hematopoietic stem and progenitor cells (HSPCs) to red blood cells. Therefore, using a set of designed marker panels, in the current study we have kinetically characterized the hematopoietic, erythroid progenitors, and terminally differentiated erythroblasts ex vivo. Furthermore, the progenitor stages were explored for expression of CD117, CD31, CD41a, CD133, and CD45, along with known key markers CD36, CD71, CD105, and GPA. Additionally, we used these marker panels to study the stage-specific phenotypic changes regulated by the epigenetic regulator; Nuclear receptor binding SET Domain protein 1 (NSD1) during erythropoiesis and to study ineffective erythropoiesis in myelodysplastic syndrome (MDS) and pure red cell aplasia (PRCA) patients. Our immunophenotyping strategy can be used to sort and study erythroid-primed hematopoietic and erythroid precursors at specified time points and to study diseases resulting from erythroid dyspoiesis. Overall, the current study explores the in-depth kinetics of phenotypic changes occurring during human erythropoiesis and applies this strategy to study normal and defective erythropoiesis.

1 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASArunim Shah
Arunim Shah
ASAkhilesh Sharma
Akhilesh Sharma
SKShobhita Katiyar
Shobhita Katiyar
AGAnshul Gupta
Anshul Gupta
CCChandra Prakash Chaturvedi
Chandra Prakash Chaturvedi
NUP98::NSD1 fusion, a cryptic translocation of t(5;11)(q35;p15.5), occurs predominantly in pediatric AML, having a poor prognostic outcome. There are limited studies on the diagnosis of NUP98::NSD1 fusion in a clinical setting, and most of the data are from Western countries. No study on the detection of this translocation has been reported from the Indian subcontinent to date. One possible reason could be the lack of availability of a potential tool to detect the fusion transcript. We have developed a real-time quantitative PCR (qRT-PCR)-based assay to detect NUP98::NSD1 fusion transcript with high sensitivity and specificity. Screening 150 AML patients (38 pediatric and 112 adults) using the assay showed the presence of fusion transcript in six patients including 03 pediatric, and 03 adult patients. We observed a prevalence rate of 7.89% (3/38) and 2.67% (3/112) fusion transcript in pediatric and adult patients, respectively. Sanger sequencing further validated the occurrence of NUP98::NSD1 fusion in all six patients. Molecular characterization of these patients revealed a co-occurrence of FLT3-ITD mutation, accompanied by altered expression of the HOX and other genes associated with AML. All six patients responded poorly to induction therapy. Overall, this is the first study to show the presence of the NUP98::NSD1 fusion transcript in Indian AML patients. Further, we demonstrate that our in-house developed qRT-PCR assay can be used to screen NUP98::NSD1 fusion in clinical settings.

2 February 2026 in The FEBS Journal
Verified
Journal Article
Closed access
SSSwati Srivastava
Swati Srivastava
SCSangita Chowdhury
Sangita Chowdhury
VUVishal Upadhyay
Vishal Upadhyay
ASArunim Shah
Arunim Shah
ASArppita Sethi
Arppita Sethi
ATArun Kumar Trivedi
Arun Kumar Trivedi

24 December 2023 in Leukemia Research Reports
Verified
Journal Article
Open access
ASAkhilesh S
Akhilesh S
ASArunim Shah
Arunim Shah
Ashish AshishAshish Ashish
Ashish Ashish
NSNitish Kumar Singh
Nitish Kumar Singh
MKManpreet Kaur
Manpreet Kaur
RSRoyana Singh
Royana Singh
Background: Chronic Myeloid Leukemia is characterized by the presence of the Philadelphia Chromosome (Ph) which contains the BCR::ABL1 fusion gene that occurs due to a reciprocal translocation between chromosomes 9 and 22. This accounts for up to 15 % of all adult leukemias [1] . Most patients treated with first line tyrosine kinase inhibitor (TKI) imatinib achieve durable response but may undergo relapse at some stage [2] . The most important mechanism that may confer imatinib resistance is point mutation within BCR::ABL kinase domain. Other generation ABL tyrosine kinase inhibitors such as dasatinib , nilotinib , bosutinib and ponatinib help to overcome imatinib resistance [3] . Sensitivity of the patient to each of the above TKIs depends upon the individual candidate mutation present. Thus, it is important to perform mutation analysis for effective therapeutic management of CML patients once they show imatinib resistance. We used direct sequencing to identify the different types of mutations responsible for resistance of imatinib treatment from north India. Methods: In this study, the patient resistance for the imatinib were analyzed for BCR::ABL kinase domain mutation by direct sequencing and the detected mutations along with their percentage prevalence were reported. Results: 329 patients with CML-CP were analyzed for BCR::ABL kinase domain mutation. Total 66 (20.06 %) patients out of 329 had mutation in at least one of the domains of BCR::ABL conferring resistance to different generations of TKI. Mutations in BCR::ABL kinase domain was observed in different domain of BCR::ABL. ATP binding P-Loop (42.42 %), Direct binding site (36.36 %), C-Loop (10.60 %), A-Loop (6.06 %), SH2 contact (3.03 %), SH3 contact (1.51 %). Conclusion: Total 20.06 % patients (66/329) show mutation in at least one of the structural motifs of BCR-ABL kinase domain, which further confer the resistance to a particular generation of TKI.

5 June 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ASArunim Shah
Arunim Shah
SKShobhita Katiyar
Shobhita Katiyar
KRKhaliqur Rahman
Khaliqur Rahman
NTNaresh Tripathy
Naresh Tripathy
CCChandra Prakash Chaturvedi
Chandra Prakash Chaturvedi

31 July 2026 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
RSRicha Singh
Richa Singh
ARAaina Singh Rathore
Aaina Singh Rathore
ASArunim Shah
Arunim Shah
PKPriyanka Kumari Keshri
Priyanka Kumari Keshri
HDHagera Dilnashin
Hagera Dilnashin
SSSurya Pratap Singh
Surya Pratap Singh